Merle 23

a synthetic analog that dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Blumberg, Peter M: 2 articles (12/2016 - 06/2011)
2.	Chen, Jinqiu: 2 articles (12/2016 - 06/2011)
3.	Keck, Gary E: 2 articles (12/2016 - 06/2011)
4.	Baumann, David O: 1 article (12/2016)
5.	Cataisson, Christophe: 1 article (12/2016)
6.	Herrmann, Michelle A: 1 article (12/2016)
7.	Kelsey, Jessica S: 1 article (12/2016)
8.	McGowan, Kevin M: 1 article (12/2016)
9.	Petersen, Mark E: 1 article (12/2016)
10.	Yuspa, Stuart H: 1 article (12/2016)

1.	Neoplasms (Cancer) 12/01/2016 - "We then examined the hyperplastic and tumor promoting activity of Merle 23 on mouse skin. " 12/01/2016 - "Merle 23 showed substantially reduced hyperplasia and was not tumor promoting at a dose comparable to that for PMA. " 02/01/2013 - "Previously, we have compared patterns of biological response to bryostatin 1, phorbol ester, and the bryostatin 1 derivative Merle 23 in two human cancer cell lines, LNCaP and U937. "
2.	Prostatic Neoplasms (Prostate Cancer) 06/01/2011 - "The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line." 06/01/2011 - "However, in U-937 human leukemia cells, Merle 23 behaves like a phorbol ester and not like bryostatin 1. Here, we characterize the behavior of Merle 23 in the human prostate cancer cell line LNCaP. "
3.	Leukemia 06/01/2011 - "However, in U-937 human leukemia cells, Merle 23 behaves like a phorbol ester and not like bryostatin 1. Here, we characterize the behavior of Merle 23 in the human prostate cancer cell line LNCaP. "
4.	Hyperplasia 12/01/2016 - "Merle 23 showed substantially reduced hyperplasia and was not tumor promoting at a dose comparable to that for PMA. "